GSK plc Key Executives
This section highlights GSK plc's key executives, including their titles and compensation details.
Find Contacts at GSK plc
(Showing 0 of )
GSK plc Earnings
This section highlights GSK plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
April 30, 2025
Time:
Before Market
Est. EPS:
$0.43
Status:
Unconfirmed
Last Earnings Results
Date:
February 05, 2025
EPS:
$0.29
Est. EPS:
$0.25
Revenue:
$8.12B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-05 | $0.25 | $0.29 |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $43.51 | $49.70 |
| Read Transcript | Q2 | 2024 | 2024-07-31 | $37.87 | $43.40 |
| Read Transcript | Q1 | 2024 | 2024-05-04 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-01-31 | $28.63 | $28.90 |
| Read Transcript | Q3 | 2023 | 2023-11-01 | $46.36 | $50.40 |
| Read Transcript | Q2 | 2023 | 2023-07-26 | $35.04 | $38.80 |
| Read Transcript | Q1 | 2023 | 2023-04-26 | $33.07 | $37.00 |
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Healthcare
Drug Manufacturers - General
$1509.00
Stock Price
$61.42B
Market Cap
-
Employees
Brentford, None
Location
Financial Statements
Access annual & quarterly financial statements for GSK plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $31.38B | $30.33B | $29.32B | $34.11B | $34.10B |
| Cost of Revenue | $9.05B | $8.56B | $9.55B | $11.60B | $11.70B |
| Gross Profit | $22.33B | $21.76B | $19.77B | $22.51B | $22.39B |
| Gross Profit Ratio | 71.16% | 71.80% | 67.42% | 66.00% | 65.68% |
| Research and Development Expenses | $6.40B | $6.22B | $5.49B | $5.28B | $5.10B |
| General and Administrative Expenses | $11.02B | $9.38B | $8.37B | $10.97B | $11.46B |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $11.02B | $9.38B | $8.37B | $10.97B | $11.46B |
| Other Expenses | $891.00M | $-590.00M | $-523.00M | $57.00M | $-1.94B |
| Operating Expenses | $18.31B | $15.02B | $13.34B | $16.31B | $14.61B |
| Cost and Expenses | $27.36B | $23.58B | $22.89B | $27.91B | $26.32B |
| Interest Income | $60.00M | $40.00M | $76.00M | $28.00M | $44.00M |
| Interest Expense | $640.00M | $775.00M | $879.00M | $784.00M | $892.00M |
| Depreciation and Amortization | $2.55B | $2.29B | $2.15B | $2.12B | $2.35B |
| EBITDA | $6.67B | $9.14B | $8.63B | $7.76B | $10.16B |
| EBITDA Ratio | 21.25% | 30.13% | 30.03% | 25.75% | 24.88% |
| Operating Income | $4.02B | $6.75B | $6.43B | $6.20B | $7.78B |
| Operating Income Ratio | 12.82% | 22.24% | 21.94% | 18.18% | 22.82% |
| Total Other Income Expenses Net | $-544.00M | $-681.00M | $-805.00M | $-758.00M | $956.00M |
| Income Before Tax | $3.48B | $6.06B | $5.63B | $5.44B | $6.97B |
| Income Before Tax Ratio | 11.08% | 19.99% | 19.19% | 15.95% | 20.43% |
| Income Tax Expense | $526.00M | $756.00M | $707.00M | $346.00M | $580.00M |
| Net Income | $2.58B | $4.93B | $4.92B | $4.38B | $5.75B |
| Net Income Ratio | 8.21% | 16.25% | 16.78% | 12.85% | 16.86% |
| EPS | $0.63 | $1.22 | $1.22 | $1.37 | $1.44 |
| EPS Diluted | $0.62 | $1.20 | $1.20 | $1.35 | $1.43 |
| Weighted Average Shares Outstanding | 4.08B | 4.05B | 4.03B | 3.20B | 3.98B |
| Weighted Average Shares Outstanding Diluted | 4.14B | 4.11B | 4.08B | 3.24B | 4.03B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.12B | $8.01B | $7.88B | $7.36B | $8.05B | $8.15B | $7.18B | $6.95B | $7.38B | $7.83B | $6.93B | $9.78B | $9.53B | $9.08B | $8.09B | $7.42B | $8.74B | $8.65B | $7.62B | $9.09B |
| Cost of Revenue | $2.56B | $2.40B | $2.08B | $1.94B | $2.34B | $2.27B | $1.93B | $1.94B | $2.24B | $2.42B | $2.18B | $3.69B | $3.68B | $2.89B | $2.55B | $2.48B | $3.17B | $2.88B | $2.45B | $3.20B |
| Gross Profit | $5.56B | $5.62B | $5.80B | $5.43B | $5.71B | $5.88B | $5.25B | $5.01B | $5.14B | $5.41B | $4.75B | $6.09B | $5.85B | $6.19B | $5.54B | $4.94B | $5.57B | $5.76B | $5.17B | $5.89B |
| Gross Profit Ratio | 68.47% | 70.10% | 73.60% | 73.70% | 71.00% | 72.10% | 73.10% | 72.00% | 69.70% | 69.10% | 68.60% | 62.30% | 61.40% | 68.20% | 68.40% | 66.60% | 63.71% | 66.63% | 67.88% | 64.81% |
| Research and Development Expenses | $2.03B | $1.46B | $1.43B | $1.37B | $2.05B | $1.57B | $1.34B | $1.26B | $1.80B | $1.35B | $1.24B | $1.17B | $1.45B | $1.49B | $1.22B | $1.12B | $1.47B | $1.14B | $1.30B | $1.19B |
| General and Administrative Expenses | $2.66B | $3.80B | $2.46B | $2.09B | $2.68B | $2.30B | $2.27B | $2.14B | $2.44B | $2.06B | $2.07B | $2.84B | $3.26B | $2.65B | $2.64B | $2.43B | $3.16B | $2.67B | $2.71B | $2.92B |
| Selling and Marketing Expenses | $- | $- | $-75.00M | $-17.00M | $-65.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $2.66B | $3.80B | $2.39B | $2.07B | $2.61B | $2.30B | $2.27B | $2.14B | $2.44B | $2.06B | $2.07B | $2.84B | $3.26B | $2.65B | $2.64B | $2.43B | $3.16B | $2.67B | $2.71B | $2.92B |
| Other Expenses | $168.00M | $167.00M | $310.00M | $- | $- | $- | $- | $-477.00M | $-965.00M | $813.00M | $364.00M | $-722.00M | $-238.00M | $114.00M | $-1.00M | $-300.00M | $1.43B | $94.00M | $1.61B | $-226.00M |
| Operating Expenses | $4.86B | $5.43B | $3.82B | $3.44B | $4.66B | $3.93B | $3.10B | $2.93B | $3.27B | $4.21B | $3.67B | $3.29B | $4.95B | $4.25B | $3.86B | $3.25B | $4.51B | $3.90B | $3.94B | $3.88B |
| Cost and Expenses | $7.42B | $7.82B | $5.90B | $5.38B | $7.00B | $6.20B | $5.04B | $4.87B | $5.51B | $6.64B | $5.85B | $6.98B | $8.63B | $7.14B | $6.42B | $5.72B | $7.68B | $6.79B | $6.38B | $7.08B |
| Interest Income | $-51.00M | $32.00M | $24.00M | $32.00M | $29.00M | $24.00M | $33.00M | $29.00M | $26.00M | $22.00M | $21.00M | $10.00M | $4.00M | $7.00M | $7.00M | $10.00M | $5.00M | $- | $1.00M | $41.00M |
| Interest Expense | $144.00M | $156.00M | $174.00M | $166.00M | $222.00M | $182.00M | $185.00M | $203.00M | $270.00M | $200.00M | $204.00M | $212.00M | $191.00M | $200.00M | $192.00M | $201.00M | $239.00M | $198.00M | $229.00M | $229.00M |
| Depreciation and Amortization | $412.00M | $951.00M | $639.00M | $549.00M | $1.18B | $579.00M | $452.00M | $640.00M | $7.00M | $956.00M | $631.00M | $704.00M | $513.00M | $986.00M | $664.00M | $361.00M | $2.68B | $641.00M | $-1.17B | $194.00M |
| EBITDA | $1.12B | $1.17B | $2.85B | $2.80B | $2.23B | $2.55B | $2.45B | $2.56B | $1.90B | $3.50B | $1.73B | $3.52B | $1.41B | $2.93B | $2.31B | $1.52B | $3.71B | $3.10B | $2.87B | $2.62B |
| EBITDA Ratio | 13.79% | 14.62% | 33.28% | 34.39% | 27.69% | 31.32% | 36.56% | 39.55% | 25.70% | 27.69% | 24.98% | 35.93% | 9.42% | 32.32% | 29.19% | 28.04% | 12.13% | 29.03% | 37.64% | 24.84% |
| Operating Income | $696.00M | $189.00M | $1.99B | $1.98B | $1.05B | $1.95B | $2.14B | $2.08B | $1.87B | $1.19B | $1.08B | $2.80B | $895.00M | $1.94B | $1.68B | $1.69B | $1.06B | $1.86B | $2.85B | $2.01B |
| Operating Income Ratio | 8.57% | 2.36% | 25.18% | 26.93% | 13.07% | 23.92% | 29.83% | 29.95% | 25.33% | 15.21% | 15.60% | 28.64% | 9.39% | 21.35% | 20.70% | 22.82% | 12.14% | 21.49% | 37.38% | 22.16% |
| Total Other Income Expenses Net | $-133.00M | $-125.00M | $-151.00M | $-135.00M | $-194.00M | $-158.00M | $-154.00M | $-175.00M | $-242.00M | $-179.00M | $-185.00M | $-707.00M | $214.00M | $365.00M | $-205.00M | $-175.00M | $-240.00M | $-187.00M | $-209.00M | $-179.00M |
| Income Before Tax | $563.00M | $64.00M | $1.50B | $1.36B | $380.00M | $1.79B | $1.99B | $1.91B | $1.63B | $1.01B | $896.00M | $2.60B | $706.00M | $1.75B | $1.47B | $1.52B | $821.00M | $1.67B | $2.64B | $1.83B |
| Income Before Tax Ratio | 6.94% | 0.80% | 18.98% | 18.42% | 4.72% | 21.98% | 27.68% | 27.43% | 22.04% | 12.93% | 12.93% | 26.56% | 7.41% | 19.26% | 18.17% | 20.46% | 9.39% | 19.33% | 34.64% | 20.19% |
| Income Tax Expense | $62.00M | $-1.00M | $191.00M | $274.00M | $-19.00M | $257.00M | $242.00M | $276.00M | $1.00M | $233.00M | $150.00M | $431.00M | $-224.00M | $380.00M | $-68.00M | $258.00M | $-18.00M | $241.00M | $201.00M | $156.00M |
| Net Income | $414.00M | $-58.00M | $1.17B | $1.05B | $350.00M | $1.46B | $1.62B | $1.49B | $1.46B | $779.00M | $838.00M | $1.80B | $749.00M | $1.37B | $1.40B | $1.07B | $677.00M | $1.24B | $2.26B | $1.56B |
| Net Income Ratio | 5.10% | -0.72% | 14.88% | 14.21% | 4.35% | 17.97% | 22.62% | 21.44% | 19.81% | 9.95% | 12.09% | 18.43% | 7.86% | 15.07% | 17.24% | 14.46% | 7.75% | 14.39% | 29.68% | 17.22% |
| EPS | $0.10 | $-0.01 | $0.29 | $0.26 | $0.09 | $0.36 | $0.40 | $0.37 | $0.37 | $0.19 | $0.21 | $0.45 | $0.19 | $0.29 | $0.35 | $0.27 | $0.17 | $0.31 | $0.57 | $0.39 |
| EPS Diluted | $0.10 | $-0.01 | $0.28 | $0.25 | $0.09 | $0.36 | $0.40 | $0.36 | $0.37 | $0.19 | $0.21 | $0.44 | $0.18 | $0.29 | $0.35 | $0.27 | $0.17 | $0.31 | $0.56 | $0.39 |
| Weighted Average Shares Outstanding | 4.08B | 4.08B | 4.08B | 4.07B | 4.06B | 4.05B | 4.05B | 4.04B | 4.03B | 4.03B | 4.03B | 4.02B | 4.01B | 4.01B | 4.00B | 3.99B | 3.98B | 3.98B | 3.98B | 3.97B |
| Weighted Average Shares Outstanding Diluted | 4.14B | 4.14B | 4.12B | 4.11B | 4.12B | 4.11B | 4.09B | 4.08B | 4.09B | 4.09B | 4.06B | 4.07B | 4.08B | 4.05B | 4.04B | 4.03B | 4.03B | 4.03B | 4.02B | 4.01B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.69B | $2.94B | $3.72B | $4.27B | $6.29B |
| Short Term Investments | $21.00M | $2.25B | $4.15B | $61.00M | $78.00M |
| Cash and Short Term Investments | $3.71B | $5.69B | $7.88B | $4.33B | $6.37B |
| Net Receivables | $- | $5.91B | $5.45B | $6.25B | $5.55B |
| Inventory | $5.67B | $5.50B | $5.15B | $5.78B | $6.00B |
| Other Current Assets | $7.61B | $1.55B | $1.45B | $1.68B | $1.87B |
| Total Current Assets | $17.00B | $18.64B | $20.77B | $18.67B | $20.25B |
| Property Plant Equipment Net | $10.07B | $9.96B | $9.62B | $10.67B | $11.01B |
| Goodwill | $6.98B | $6.81B | $7.05B | $10.55B | $10.60B |
| Intangible Assets | $15.52B | $14.77B | $14.32B | $30.08B | $29.82B |
| Goodwill and Intangible Assets | $22.50B | $21.58B | $21.36B | $40.63B | $40.42B |
| Long Term Investments | $1.21B | $2.14B | $-2.61B | $2.15B | $3.35B |
| Tax Assets | $6.76B | $6.05B | $5.66B | $5.22B | $4.29B |
| Other Non-Current Assets | $1.93B | $634.00M | $5.35B | $1.75B | $1.12B |
| Total Non-Current Assets | $42.47B | $40.36B | $39.38B | $60.43B | $60.18B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $59.46B | $59.01B | $60.15B | $79.10B | $80.43B |
| Account Payables | $3.46B | $3.72B | $3.87B | $4.54B | $4.36B |
| Short Term Debt | $2.35B | $2.81B | $3.95B | $3.60B | $3.73B |
| Tax Payables | $703.00M | $500.00M | $471.00M | $489.00M | $545.00M |
| Deferred Revenue | $- | $222.00M | $299.00M | $1.56B | $1.82B |
| Other Current Liabilities | $15.18B | $13.82B | $14.22B | $14.74B | $13.16B |
| Total Current Liabilities | $21.70B | $21.07B | $22.81B | $23.67B | $22.15B |
| Long Term Debt | $14.64B | $15.21B | $17.04B | $20.57B | $23.43B |
| Deferred Revenue Non-Current | $165.00M | $254.00M | $83.00M | $85.00M | $21.00M |
| Deferred Tax Liabilities Non-Current | $382.00M | $311.00M | $289.00M | $3.56B | $3.60B |
| Other Non-Current Liabilities | $9.50B | $9.37B | $9.83B | $9.88B | $10.43B |
| Total Non-Current Liabilities | $24.68B | $25.14B | $27.24B | $34.09B | $37.48B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $46.38B | $46.21B | $50.05B | $57.76B | $59.62B |
| Preferred Stock | $- | $- | $48.00M | $- | $- |
| Common Stock | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B |
| Retained Earnings | $7.80B | $7.24B | $4.36B | $7.94B | $6.75B |
| Accumulated Other Comprehensive Income Loss | $- | $1.60B | $-48.00M | $642.00M | $1.55B |
| Other Total Stockholders Equity | $4.53B | $3.16B | $3.70B | $3.27B | $3.09B |
| Total Stockholders Equity | $13.67B | $13.35B | $10.60B | $15.05B | $14.59B |
| Total Equity | $13.09B | $12.79B | $10.10B | $21.34B | $20.81B |
| Total Liabilities and Stockholders Equity | $59.46B | $59.01B | $60.15B | $79.10B | $80.43B |
| Minority Interest | $-585.00M | $-552.00M | $-502.00M | $6.29B | $6.22B |
| Total Liabilities and Total Equity | $59.46B | $59.01B | $60.15B | $79.10B | $80.43B |
| Total Investments | $1.23B | $4.39B | $1.54B | $2.21B | $3.42B |
| Total Debt | $16.99B | $18.02B | $20.99B | $24.17B | $27.15B |
| Net Debt | $13.29B | $15.08B | $17.26B | $19.90B | $20.86B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.69B | $3.19B | $2.96B | $2.79B | $2.94B | $3.18B | $3.14B | $2.89B | $3.72B | $3.61B | $6.46B | $10.97B | $4.27B | $3.45B | $3.50B | $4.76B | $6.29B | $4.28B | $8.17B | $4.77B |
| Short Term Investments | $21.00M | $20.00M | $21.00M | $1.30B | $2.25B | $3.51B | $3.36B | $4.08B | $4.15B | $3.56B | $67.00M | $3.01B | $61.00M | $61.00M | $59.00M | $60.00M | $78.00M | $83.00M | $87.00M | $86.00M |
| Cash and Short Term Investments | $3.71B | $3.21B | $2.98B | $4.09B | $5.18B | $6.68B | $6.50B | $6.97B | $7.88B | $7.16B | $6.53B | $13.98B | $4.33B | $3.51B | $3.56B | $4.82B | $6.37B | $4.37B | $8.25B | $4.86B |
| Net Receivables | $- | $- | $7.26B | $6.83B | $5.91B | $8.54B | $6.78B | $6.83B | $5.45B | $7.51B | $6.46B | $8.30B | $8.03B | $7.70B | $6.90B | $7.18B | $7.26B | $8.42B | $7.50B | $8.89B |
| Inventory | $5.67B | $5.92B | $5.86B | $5.70B | $5.50B | $5.48B | $5.51B | $5.36B | $5.15B | $4.66B | $4.66B | $6.00B | $5.78B | $6.24B | $6.33B | $6.22B | $6.00B | $6.44B | $6.40B | $5.95B |
| Other Current Assets | $7.61B | $301.00M | $663.00M | $577.00M | $1.55B | $533.00M | $556.00M | $556.00M | $1.45B | $921.00M | $36.53B | $708.00M | $1.68B | $799.00M | $772.00M | $308.00M | $1.87B | $654.00M | $833.00M | $2.32B |
| Total Current Assets | $17.00B | $17.30B | $16.76B | $17.20B | $18.64B | $21.24B | $19.35B | $19.72B | $20.77B | $20.25B | $54.19B | $28.99B | $18.67B | $18.25B | $17.57B | $18.52B | $20.25B | $19.88B | $22.98B | $22.02B |
| Property Plant Equipment Net | $10.07B | $9.72B | $9.82B | $9.87B | $9.96B | $9.45B | $9.31B | $9.41B | $9.62B | $9.65B | $9.15B | $10.70B | $10.67B | $10.67B | $10.59B | $10.63B | $11.01B | $11.21B | $11.43B | $11.40B |
| Goodwill | $6.98B | $6.68B | $6.96B | $6.98B | $6.81B | $6.97B | $6.72B | $6.86B | $7.05B | $7.20B | $5.91B | $10.71B | $10.55B | $10.58B | $10.44B | $10.44B | $10.60B | $10.89B | $11.00B | $10.90B |
| Intangible Assets | $15.52B | $15.01B | $15.47B | $15.67B | $14.77B | $15.29B | $15.53B | $14.16B | $14.32B | $15.59B | $11.37B | $30.47B | $30.08B | $30.24B | $29.33B | $29.42B | $29.82B | $30.66B | $31.26B | $31.50B |
| Goodwill and Intangible Assets | $22.50B | $21.69B | $22.43B | $22.64B | $21.58B | $22.27B | $22.25B | $21.02B | $21.36B | $22.78B | $17.28B | $41.17B | $40.63B | $40.82B | $39.77B | $39.86B | $40.42B | $41.55B | $42.26B | $42.40B |
| Long Term Investments | $1.21B | $1.11B | $1.15B | $1.28B | $2.14B | $-2.36B | $-2.01B | $-2.75B | $-2.61B | $-1.93B | $1.66B | $-1.27B | $2.15B | $2.76B | $3.18B | $3.69B | $3.35B | $2.89B | $2.48B | $2.10B |
| Tax Assets | $6.76B | $6.29B | $6.17B | $5.86B | $6.05B | $5.61B | $5.80B | $5.61B | $5.66B | $4.82B | $4.95B | $5.26B | $5.22B | $4.88B | $4.71B | $4.31B | $4.29B | $4.38B | $4.46B | $4.17B |
| Other Non-Current Assets | $1.93B | $1.94B | $1.73B | $1.65B | $634.00M | $4.65B | $4.77B | $5.58B | $5.35B | $4.74B | $1.81B | $4.83B | $1.75B | $1.31B | $1.20B | $1.05B | $1.12B | $1.02B | $1.04B | $2.29B |
| Total Non-Current Assets | $42.47B | $40.75B | $41.30B | $41.31B | $40.36B | $39.62B | $40.11B | $38.88B | $39.38B | $40.06B | $34.86B | $60.70B | $60.43B | $60.44B | $59.45B | $59.55B | $60.18B | $61.05B | $61.66B | $62.36B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $59.46B | $58.05B | $58.07B | $58.51B | $59.01B | $60.86B | $59.46B | $58.60B | $60.15B | $60.31B | $89.05B | $89.69B | $79.10B | $78.69B | $77.01B | $78.08B | $80.43B | $80.93B | $84.64B | $84.38B |
| Account Payables | $3.46B | $14.38B | $12.60B | $12.99B | $3.72B | $14.41B | $12.56B | $12.86B | $3.87B | $14.78B | $13.35B | $15.75B | $4.54B | $13.61B | $12.99B | $13.04B | $4.36B | $13.74B | $13.70B | $13.44B |
| Short Term Debt | $2.35B | $2.81B | $3.37B | $2.62B | $2.81B | $4.84B | $5.92B | $4.26B | $3.95B | $2.79B | $3.33B | $4.10B | $3.60B | $4.87B | $5.04B | $3.17B | $3.73B | $4.91B | $5.96B | $7.26B |
| Tax Payables | $703.00M | $568.00M | $731.00M | $720.00M | $500.00M | $286.00M | $544.00M | $424.00M | $471.00M | $129.00M | $295.00M | $783.00M | $489.00M | $717.00M | $411.00M | $660.00M | $545.00M | $428.00M | $685.00M | $815.00M |
| Deferred Revenue | $- | $- | $731.00M | $720.00M | $500.00M | $941.00M | $1.29B | $- | $- | $- | $- | $- | $1.56B | $1.55B | $1.34B | $1.75B | $1.82B | $1.35B | $1.71B | $1.96B |
| Other Current Liabilities | $15.18B | $3.70B | $3.65B | $3.52B | $14.04B | $2.85B | $3.09B | $3.15B | $14.52B | $3.25B | $20.86B | $3.64B | $15.04B | $3.23B | $2.95B | $3.40B | $13.16B | $3.09B | $3.58B | $3.82B |
| Total Current Liabilities | $21.70B | $21.46B | $20.34B | $19.85B | $21.07B | $22.39B | $22.11B | $20.70B | $22.81B | $20.95B | $37.84B | $24.28B | $23.67B | $22.42B | $21.39B | $20.27B | $22.15B | $22.18B | $23.92B | $25.34B |
| Long Term Debt | $14.64B | $13.24B | $13.58B | $15.16B | $15.21B | $13.09B | $15.55B | $16.64B | $17.04B | $19.32B | $18.78B | $29.23B | $20.57B | $20.74B | $20.44B | $23.05B | $23.43B | $23.33B | $25.73B | $24.74B |
| Deferred Revenue Non-Current | $165.00M | $- | $- | $- | $254.00M | $2.91B | $2.96B | $- | $83.00M | $- | $- | $- | $85.00M | $4.25B | $4.19B | $4.33B | $21.00M | $4.75B | $5.03B | $4.63B |
| Deferred Tax Liabilities Non-Current | $382.00M | $294.00M | $290.00M | $288.00M | $311.00M | $402.00M | $500.00M | $290.00M | $289.00M | $364.00M | $149.00M | $3.67B | $3.56B | $3.67B | $3.59B | $3.57B | $3.60B | $3.92B | $3.97B | $3.90B |
| Other Non-Current Liabilities | $9.50B | $9.60B | $10.08B | $9.99B | $9.37B | $6.55B | $9.14B | $9.65B | $9.83B | $10.96B | $9.64B | $9.88B | $9.88B | $10.12B | $10.02B | $10.18B | $10.43B | $10.87B | $10.89B | $10.31B |
| Total Non-Current Liabilities | $24.68B | $23.14B | $23.95B | $25.44B | $25.14B | $25.85B | $25.19B | $26.59B | $27.24B | $30.64B | $28.57B | $42.78B | $34.09B | $34.52B | $34.05B | $36.79B | $37.48B | $38.12B | $40.58B | $38.95B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $46.38B | $44.60B | $44.30B | $45.28B | $46.21B | $48.24B | $47.30B | $47.28B | $50.05B | $51.60B | $66.41B | $67.06B | $57.76B | $56.94B | $55.43B | $57.07B | $59.62B | $60.30B | $64.50B | $64.28B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $48.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B | $1.35B |
| Retained Earnings | $7.80B | $8.19B | $8.58B | $7.93B | $7.24B | $7.02B | $6.42B | $5.66B | $4.36B | $2.59B | $9.82B | $9.64B | $7.94B | $7.78B | $7.38B | $6.70B | $6.75B | $7.05B | $6.62B | $6.35B |
| Accumulated Other Comprehensive Income Loss | $- | $- | $969.00M | $1.09B | $1.60B | $1.32B | $1.48B | $1.37B | $-48.00M | $1.77B | $1.76B | $1.76B | $642.00M | $3.00B | $3.44B | $3.52B | $2.67B | $2.60B | $2.35B | $2.12B |
| Other Total Stockholders Equity | $4.53B | $4.47B | $3.47B | $3.47B | $3.16B | $3.45B | $3.45B | $3.45B | $3.70B | $3.44B | $3.44B | $3.44B | $3.27B | $3.30B | $3.21B | $3.16B | $3.09B | $3.28B | $3.28B | $2.89B |
| Total Stockholders Equity | $13.67B | $14.01B | $14.37B | $13.84B | $13.35B | $13.13B | $12.69B | $11.82B | $10.60B | $9.15B | $16.37B | $16.18B | $15.05B | $15.43B | $15.38B | $14.87B | $14.59B | $14.29B | $13.59B | $13.09B |
| Total Equity | $13.09B | $13.45B | $13.77B | $13.23B | $12.79B | $12.62B | $12.16B | $11.31B | $10.10B | $8.72B | $22.64B | $22.63B | $21.34B | $21.75B | $21.58B | $21.01B | $20.81B | $20.62B | $20.14B | $20.10B |
| Total Liabilities and Stockholders Equity | $59.46B | $58.05B | $58.07B | $58.51B | $59.01B | $60.86B | $59.46B | $58.60B | $60.15B | $60.31B | $89.05B | $89.69B | $79.10B | $78.69B | $77.01B | $78.08B | $80.43B | $80.93B | $84.64B | $84.38B |
| Minority Interest | $-585.00M | $-555.00M | $-602.00M | $-611.00M | $-552.00M | $-514.00M | $-532.00M | $-508.00M | $-502.00M | $-436.00M | $6.27B | $6.45B | $6.29B | $6.32B | $6.20B | $6.14B | $6.22B | $6.34B | $6.54B | $7.00B |
| Total Liabilities and Total Equity | $59.46B | $58.05B | $58.07B | $58.51B | $59.01B | $60.86B | $59.46B | $58.60B | $60.15B | $60.31B | $89.05B | $89.69B | $79.10B | $78.69B | $77.01B | $78.08B | $80.43B | $80.93B | $84.64B | $84.38B |
| Total Investments | $1.23B | $1.10B | $1.17B | $2.58B | $4.39B | $1.14B | $1.35B | $1.34B | $1.54B | $1.63B | $1.73B | $1.74B | $2.21B | $2.82B | $3.23B | $3.75B | $3.42B | $2.97B | $2.56B | $2.19B |
| Total Debt | $16.99B | $16.06B | $16.94B | $17.77B | $18.02B | $20.84B | $21.47B | $20.91B | $20.99B | $22.11B | $22.11B | $33.33B | $24.17B | $25.61B | $25.48B | $26.22B | $27.15B | $28.25B | $31.69B | $32.01B |
| Net Debt | $13.29B | $12.87B | $13.98B | $14.98B | $15.08B | $17.66B | $18.33B | $18.02B | $17.26B | $18.51B | $15.65B | $22.36B | $19.90B | $22.15B | $21.98B | $21.46B | $20.86B | $23.96B | $23.52B | $27.24B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $2.95B | $4.93B | $4.92B | $5.10B | $6.39B |
| Depreciation and Amortization | $2.55B | $2.29B | $2.30B | $2.52B | $624.00M |
| Deferred Income Tax | $- | $-865.00M | $-784.00M | $-318.00M | $80.00M |
| Stock Based Compensation | $344.00M | $307.00M | $346.00M | $343.00M | $337.00M |
| Change in Working Capital | $2.09B | $-841.00M | $271.00M | $-473.00M | $120.00M |
| Accounts Receivables | $340.00M | $-649.00M | $-616.00M | $-1.16B | $-383.00M |
| Inventory | $-294.00M | $-424.00M | $-269.00M | $25.00M | $119.00M |
| Accounts Payables | $- | $-15.00M | $494.00M | $229.00M | $225.00M |
| Other Working Capital | $2.04B | $247.00M | $662.00M | $435.00M | $159.00M |
| Other Non Cash Items | $-1.38B | $945.00M | $351.00M | $756.00M | $848.00M |
| Net Cash Provided by Operating Activities | $6.55B | $6.77B | $7.40B | $7.95B | $8.44B |
| Investments in Property Plant and Equipment | $-1.40B | $-1.31B | $-2.26B | $-2.93B | $-2.24B |
| Acquisitions Net | $1.37B | $-1.47B | $-3.14B | $185.00M | $3.01B |
| Purchases of Investments | $- | $-123.00M | $-144.00M | $1.76B | $-1.00M |
| Sales Maturities of Investments | $21.00M | $72.00M | $1.00M | $18.00M | $3.27B |
| Other Investing Activities | $-1.22B | $1.24B | $-3.23B | $-808.00M | $-1.88B |
| Net Cash Used for Investing Activities | $-1.23B | $-1.59B | $-8.77B | $-1.78B | $2.16B |
| Debt Repayment | $-1.17B | $-2.37B | $-771.00M | $-2.00B | $-4.01B |
| Common Stock Issued | $20.00M | $10.00M | $25.00M | $21.00M | $29.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $-2.44B | $-2.25B | $-3.47B | $-4.00B | $-3.98B |
| Other Financing Activities | $-1.14B | $-1.03B | $5.06B | $-1.61B | $-2.18B |
| Net Cash Used Provided by Financing Activities | $-4.73B | $-5.64B | $823.00M | $-7.59B | $-10.13B |
| Effect of Forex Changes on Cash | $-54.00M | $-99.00M | $152.00M | $-29.00M | $-39.00M |
| Net Change in Cash | $545.00M | $-567.00M | $-394.00M | $-1.44B | $431.00M |
| Cash at End of Period | $3.40B | $2.86B | $3.42B | $3.82B | $5.26B |
| Cash at Beginning of Period | $2.86B | $3.42B | $3.82B | $5.26B | $4.83B |
| Operating Cash Flow | $6.55B | $6.77B | $7.40B | $7.95B | $8.44B |
| Capital Expenditure | $-2.98B | $-2.34B | $-2.26B | $-2.93B | $-2.24B |
| Free Cash Flow | $3.57B | $4.42B | $5.14B | $5.02B | $6.20B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $501.00M | $-58.00M | $1.17B | $1.05B | $350.00M | $1.53B | $1.75B | $1.63B | $1.62B | $779.00M | $350.00M | $2.17B | $930.00M | $1.37B | $1.54B | $1.26B | $839.00M | $1.43B | $2.44B | $1.68B |
| Depreciation and Amortization | $412.00M | $951.00M | $639.00M | $549.00M | $1.18B | $579.00M | $452.00M | $640.00M | $7.00M | $956.00M | $631.00M | $704.00M | $513.00M | $986.00M | $664.00M | $361.00M | $954.00M | $641.00M | $-1.17B | $194.00M |
| Deferred Income Tax | $- | $- | $- | $- | $-865.00M | $- | $- | $- | $-784.00M | $- | $- | $- | $-1.00B | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $307.00M | $- | $- | $- | $346.00M | $- | $- | $- | $343.00M | $- | $- | $- | $393.00M | $- | $- | $- |
| Change in Working Capital | $3.76B | $-714.00M | $-644.00M | $-311.00M | $1.81B | $164.00M | $-1.99B | $-840.00M | $938.00M | $-469.00M | $473.00M | $-671.00M | $2.99B | $132.00M | $-1.16B | $-539.00M | $2.35B | $-968.00M | $864.00M | $-1.34B |
| Accounts Receivables | $- | $- | $- | $- | $-794.00M | $- | $- | $- | $-158.00M | $- | $- | $- | $-780.00M | $- | $- | $- | $-224.00M | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-424.00M | $- | $- | $- | $-269.00M | $- | $- | $- | $51.00M | $- | $- | $- | $119.00M | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $79.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $3.76B | $-714.00M | $-322.00M | $-607.00M | $2.95B | $164.00M | $-1.99B | $-840.00M | $1.36B | $-469.00M | $473.00M | $-174.00M | $2.04B | $50.00M | $115.00M | $-1.38B | $956.00M | $-672.00M | $1.57B | $-796.00M |
| Other Non Cash Items | $-2.34B | $1.96B | $992.00M | $753.00M | $2.85B | $-65.00M | $1.10B | $-1.38B | $-227.00M | $55.00M | $181.00M | $342.00M | $-663.00M | $76.00M | $250.00M | $-751.00M | $-289.00M | $-242.00M | $621.00M | $432.00M |
| Net Cash Provided by Operating Activities | $2.33B | $2.14B | $882.00M | $939.00M | $2.97B | $2.21B | $1.31B | $53.00M | $1.91B | $1.32B | $1.64B | $2.54B | $3.77B | $2.56B | $1.29B | $331.00M | $3.85B | $861.00M | $2.76B | $965.00M |
| Investments in Property Plant and Equipment | $-544.00M | $-305.00M | $-442.00M | $-563.00M | $-783.00M | $-497.00M | $-535.00M | $-529.00M | $-751.00M | $-480.00M | $-426.00M | $-601.00M | $-632.00M | $-1.28B | $-661.00M | $-354.00M | $-845.00M | $-648.00M | $-402.00M | $-344.00M |
| Acquisitions Net | $-96.00M | $-17.00M | $-33.00M | $-721.00M | $-2.00M | $-73.00M | $-542.00M | $-52.00M | $-6.00M | $-2.99B | $-73.00M | $-70.00M | $-33.00M | $-34.00M | $337.00M | $-85.00M | $-1.00M | $58.00M | $2.70B | $135.00M |
| Purchases of Investments | $- | $- | $-32.00M | $-18.00M | $-31.00M | $-33.00M | $-3.00M | $-56.00M | $-22.00M | $-63.00M | $-14.00M | $-45.00M | $-16.00M | $-24.00M | $-20.00M | $18.00M | $-15.00M | $-189.00M | $-182.00M | $-26.00M |
| Sales Maturities of Investments | $- | $57.00M | $1.24B | $1.08B | $1.02B | $72.00M | $799.00M | $11.00M | $1.00M | $114.00M | $1.00M | $- | $7.00M | $24.00M | $404.00M | $62.00M | $135.00M | $263.00M | $2.83B | $45.00M |
| Other Investing Activities | $-479.00M | $-466.00M | $-3.00M | $24.00M | $756.00M | $40.00M | $-683.00M | $218.00M | $238.00M | $-678.00M | $-33.00M | $-2.92B | $304.00M | $135.00M | $139.00M | $311.00M | $674.00M | $-44.00M | $-2.11B | $132.00M |
| Net Cash Used for Investing Activities | $-1.12B | $-731.00M | $731.00M | $-201.00M | $207.00M | $-491.00M | $-964.00M | $-408.00M | $-540.00M | $-4.09B | $-545.00M | $-3.59B | $-361.00M | $-1.18B | $-185.00M | $-48.00M | $-52.00M | $-560.00M | $2.83B | $-58.00M |
| Debt Repayment | $244.00M | $-548.00M | $-539.00M | $-323.00M | $-2.77B | $-1.04B | $1.04B | $408.00M | $-406.00M | $-1.15B | $-2.82B | $-51.00M | $-1.42B | $-226.00M | $-347.00M | $-49.00M | $-516.00M | $-2.83B | $-548.00M | $-116.00M |
| Common Stock Issued | $- | $1.00M | $1.00M | $18.00M | $1.00M | $- | $3.00M | $8.00M | $- | $8.00M | $3.00M | $17.00M | $1.00M | $1.00M | $4.00M | $15.00M | $1.00M | $2.00M | $3.00M | $23.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $-2.00M | $- | $- | $4.00M | $-7.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $-612.00M | $-612.00M | $-652.00M | $-568.00M | $-568.00M | $-567.00M | $-557.00M | $-555.00M | $-654.00M | $-705.00M | $-1.16B | $-952.00M | $-951.00M | $-951.00M | $-1.15B | $-946.00M | $-946.00M | $-946.00M | $-1.14B | $-941.00M |
| Other Financing Activities | $-474.00M | $-81.00M | $-124.00M | $-116.00M | $-255.00M | $-151.00M | $-451.00M | $-177.00M | $-278.00M | $522.00M | $-521.00M | $8.97B | $-407.00M | $-218.00M | $-551.00M | $-396.00M | $-714.00M | $-505.00M | $-940.00M | $-18.00M |
| Net Cash Used Provided by Financing Activities | $-842.00M | $-1.24B | $-1.31B | $-989.00M | $-3.31B | $-1.76B | $31.00M | $-318.00M | $-1.34B | $-1.33B | $-4.49B | $7.97B | $-2.77B | $-1.39B | $-2.04B | $-1.38B | $-2.17B | $-4.28B | $-2.63B | $-1.05B |
| Effect of Forex Changes on Cash | $7.00M | $-34.00M | $-8.00M | $-19.00M | $-34.00M | $23.00M | $-57.00M | $-31.00M | $46.00M | $23.00M | $71.00M | $12.00M | $-8.00M | $13.00M | $1.00M | $-35.00M | $-22.00M | $-45.00M | $-14.00M | $42.00M |
| Net Change in Cash | $375.00M | $149.00M | $172.00M | $-146.00M | $-241.00M | $-18.00M | $317.00M | $-704.00M | $73.00M | $-4.07B | $-3.33B | $6.93B | $625.00M | $-2.00M | $-938.00M | $-1.13B | $1.61B | $-4.02B | $2.95B | $-103.00M |
| Cash at End of Period | $3.40B | $3.03B | $2.96B | $2.79B | $2.94B | $3.02B | $3.04B | $2.72B | $3.42B | $3.35B | $7.43B | $10.75B | $3.82B | $3.19B | $3.20B | $4.13B | $5.26B | $3.66B | $7.68B | $4.73B |
| Cash at Beginning of Period | $3.03B | $2.88B | $2.79B | $2.94B | $3.18B | $3.04B | $2.72B | $3.42B | $3.35B | $7.43B | $10.75B | $3.82B | $3.19B | $3.20B | $4.13B | $5.26B | $3.66B | $7.68B | $4.73B | $4.83B |
| Operating Cash Flow | $2.33B | $2.14B | $882.00M | $939.00M | $2.97B | $2.21B | $1.31B | $53.00M | $1.91B | $1.32B | $1.64B | $2.54B | $3.77B | $2.56B | $1.29B | $331.00M | $3.85B | $861.00M | $2.76B | $965.00M |
| Capital Expenditure | $-1.14B | $-842.00M | $-442.00M | $-563.00M | $-783.00M | $-497.00M | $-535.00M | $-529.00M | $-751.00M | $-480.00M | $-426.00M | $-601.00M | $-632.00M | $-1.28B | $-661.00M | $-354.00M | $-845.00M | $-648.00M | $-402.00M | $-344.00M |
| Free Cash Flow | $1.19B | $1.31B | $440.00M | $376.00M | $2.19B | $1.72B | $772.00M | $-476.00M | $1.15B | $841.00M | $1.21B | $1.94B | $3.13B | $1.28B | $631.00M | $-23.00M | $3.01B | $213.00M | $2.36B | $621.00M |
GSK plc Dividends
Explore GSK plc's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
4.45%
Dividend Payout Ratio
94.91%
Dividend Paid & Capex Coverage Ratio
1.21x
GSK plc Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $16 | $16 | February 20, 2025 | February 21, 2025 | April 10, 2025 | |
| $15 | $15 | November 14, 2024 | November 15, 2024 | January 09, 2025 | |
| $15 | $15 | August 15, 2024 | August 16, 2024 | October 10, 2024 | |
| $15 | $15 | May 16, 2024 | May 17, 2024 | July 11, 2024 | |
| $16 | $16 | February 22, 2024 | February 23, 2024 | April 11, 2024 | |
| $14 | $14 | November 16, 2023 | November 17, 2023 | January 11, 2024 | |
| $14 | $14 | August 17, 2023 | August 18, 2023 | October 12, 2023 | |
| $14 | $14 | May 18, 2023 | May 19, 2023 | July 13, 2023 | |
| $13.75 | $13.75 | February 23, 2023 | February 24, 2023 | April 13, 2023 | February 01, 2023 |
| $13.75 | $13.75 | November 17, 2022 | November 18, 2022 | January 12, 2023 | November 02, 2022 |
| $16.25 | $16.25 | August 18, 2022 | August 19, 2022 | October 06, 2022 | July 27, 2022 |
| $14 | $17.5 | May 19, 2022 | May 20, 2022 | July 01, 2022 | April 27, 2022 |
| $23 | $28.75 | February 24, 2022 | February 25, 2022 | April 07, 2022 | February 09, 2022 |
| $19 | $23.75 | November 18, 2021 | November 19, 2021 | January 13, 2022 | October 27, 2021 |
| $19 | $23.75 | August 19, 2021 | August 20, 2021 | October 07, 2021 | July 28, 2021 |
| $19 | $23.75 | May 20, 2021 | May 21, 2021 | July 08, 2021 | April 28, 2021 |
| $23 | $28.75 | February 18, 2021 | February 19, 2021 | April 08, 2021 | February 03, 2021 |
| $19 | $23.75 | November 12, 2020 | November 13, 2020 | January 14, 2021 | October 28, 2020 |
| $19 | $23.75 | August 13, 2020 | August 14, 2020 | October 08, 2020 | July 29, 2020 |
| $19 | $23.75 | May 14, 2020 | May 15, 2020 | July 09, 2020 | January 08, 2020 |
GSK plc News
Read the latest news about GSK plc, including recent articles, headlines, and updates.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GSK.L.